Literature DB >> 23829922

Cystic and alveolar echinococcosis.

Marija Stojkovic1, Thomas Junghanss.   

Abstract

Echinococcosis of the CNS is very rare. Cystic (CE) and alveolar echininococcosis (AE) vary in their clinical manifestations, course of disease, and prognosis, to the extent that clinicians should look at these two parasitic infections as distinctly different entities. CE causes displacement and pressure atrophy, while AE expands by infiltrative growth. Due to the embolic nature of CE and AE, CNS lesions are most commonly localized supratentorially in the middle cerebral artery. Symptoms and clinical signs are those of space-occupying lesions. Diagnosis is primarily based on imaging (MRI, CT); serology can help to confirm the diagnosis, but is unreliable. In vivo MRS techniques for immobile intracranial CE lesions have become feasible and will assist in diagnosing such lesions in the future. Patients with cerebral CE and AE need an individual therapeutic approach and should generally be managed by a multidisciplinary team of clinicians experienced in the management of CE and neurosurgeons. A minimum follow-up of 5 years, but ideally 10 years, is necessary. Treatment is difficult in advanced disease, in particular in AE, when curative surgery is not possible. AE and CE are among the most neglected infectious diseases and urgently need more attention to improve early detection in exposed populations, diagnosis, and treatment.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Echinococcus granulosus; Echinococcus multilocularis; alveolar echinococcosis; cystic echinococcosis; hydatid disease

Mesh:

Year:  2013        PMID: 23829922     DOI: 10.1016/B978-0-444-53490-3.00026-1

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  7 in total

1.  Autochthonous human alveolar echinococcosis in a Hungarian patient.

Authors:  Balázs Dezsényi; Tamás Strausz; Zita Makrai; Judit Csomor; József Danka; Peter Kern; Giovanni Rezza; Thomas F E Barth; Adriano Casulli
Journal:  Infection       Date:  2016-06-28       Impact factor: 3.553

2.  Imaging in neurologic infections I: bacterial and parasitic diseases.

Authors:  Pooja Raibagkar; Martha R Neagu; Jennifer L Lyons; Joshua P Klein
Journal:  Curr Infect Dis Rep       Date:  2014-12       Impact factor: 3.725

3.  Proposal of a computed tomography classification for hepatic alveolar echinococcosis.

Authors:  Tilmann Graeter; Wolfgang Kratzer; Suemeyra Oeztuerk; Mark Martin Haenle; Richard Andrew Mason; Andreas Hillenbrand; Thomas Kull; Thomas F Barth; Peter Kern; Beate Gruener
Journal:  World J Gastroenterol       Date:  2016-04-07       Impact factor: 5.742

4.  Comparative study of indocyanine green (ICG)-R15 and Albumin-Indocyanine Green Evaluation (ALICE) grading system in the prediction of posthepatectomy liver failure and postoperative mortality in patients with hepatic alveolar echinococcosis.

Authors:  Yuxin Liang; Zilong Zhang; Zonglin Dai; Rui Cao; Deyuan Zhong; Chunyou Lai; Yutong Yao; Tianhang Feng; Xiaolun Huang
Journal:  BMC Gastroenterol       Date:  2022-06-14       Impact factor: 2.847

5.  Dynamic changes of DC and T cell subsets in mice during Echinococcus multilocularis infection.

Authors:  Xiao-Li Wei; Qi Xu; Fu-Lati Rexiti; Ming Zhu; Ren-Yong Lin; Hao Wen
Journal:  Cent Eur J Immunol       Date:  2014-04-17       Impact factor: 2.085

6.  Outcome after Discontinuing Long-Term Benzimidazole Treatment in 11 Patients with Non-resectable Alveolar Echinococcosis with Negative FDG-PET/CT and Anti-EmII/3-10 Serology.

Authors:  Rudolf W Ammann; Katrin D M Stumpe; Felix Grimm; Peter Deplazes; Sabine Huber; Kaja Bertogg; Dorothee R Fischer; Beat Müllhaupt
Journal:  PLoS Negl Trop Dis       Date:  2015-09-21

7.  Expression of Toll-Like Receptors 2 and 4 and Related Cytokines in Patients with Hepatic Cystic and Alveolar Echinococcosis.

Authors:  Tuerhongjiang Tuxun; Hai-Zhang Ma; Shadike Apaer; Heng Zhang; Amina Aierken; Yu-Peng Li; Ren-Yong Lin; Jin-Ming Zhao; Jin-Hui Zhang; Hao Wen
Journal:  Mediators Inflamm       Date:  2015-11-09       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.